Migraine with Brainstem Aura Market Size, Share & Trends Analysis Report By Diagnosis (Magnetic Resonance Imaging (MRI), Computerized Tomography (CT), Others), By Treatment (Abortive Medication, Preventive Medication), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), By End-User (Hospitals and Clinics, Diagnostic Centers, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global migraine with brainstem aura market size is estimated to grow at a CAGR of 4.85% during the forecast period (2023–2031). The expansion of the migraine with brainstem aura market is primarily attributable to rising cases of migraine with aura worldwide, ultimately leading to the growing incidence of migraine with brainstem aura. In addition, the surging prevalence of epilepsy, which is a neurological disease worldwide, is further boosting the global migraine with brainstem aura market. Moreover, the technological innovations and developments in the diagnostic field of migraine with brainstem aura and neuroscience are creating market growth opportunities.

A rare subtype of migraine with aura is migraine with brainstem aura, also referred to as "basilar-type migraine" or "basilar migraine." Migraine is a neurological disorder defined by severe, recurrent migraines that may accompany additional symptoms. Migraine with Brainstem Aura is distinguished by the manifestation of aura symptoms originating from the brainstem, the critical region situated at the base of the brain that regulates numerous bodily processes.

Migraine with aura is a distinct subtype of migraine characterized by the presence of visual, sensory, or additional neurological disruptions preceding or concurrent with the convulsion stage. Transient Ischemic Attacks (TIAs) and other neurological disorders can be confounded with migraine with brainstem aura, which is a relatively uncommon condition. Patients who exhibit these symptoms must promptly seek medical evaluation and diagnosis to ascertain the appropriate course of treatment and exclude alternative potential causes.

Market Dynamics

Migraine with Brainstem Aura Market Drivers

Rising Prevalence of Migraine with Aura

The condition known as migraine with brainstem aura Aura is a chronic disease that impacts a range of 6.6% to 10% of those diagnosed with migraine accompanied by aura. Migraine, accompanied by a typical aura, is an exceptionally widespread disorder. An article published in the Journal of Headache and Pain in May 2019 stated that migraines with auras impact 8% of the population.

Migraine aura (MA) symptoms are typically visual, sensory, or linguistic disturbances that are entirely reversible. Visual aura symptoms (VASs) are the most prevalent, manifesting in 98–99% of manifesting auras (MAs), while sensory and linguistic disturbances transpire in 36% and 10% of auras, respectively. Thus, the surging prevalence of migraine with aura will ultimately boost migraine with brainstem aura cases worldwide, thereby driving global market growth.

Growing Incidence of Epilepsy

Epilepsy is a persistent, non-communicable neurological disorder that impacts individuals across various age groups. The condition can be recognized by recurring seizures, which manifest as brief, uncontrollable movements that can affect either a specific body region (partial) or the entire body (generalized). These seizures may occasionally be accompanied by loss of consciousness and the inability to control bowel or bladder function.

According to WHO, epilepsy affects around 50 million individuals on a global scale, rendering it a prevalent neurological disorder. Moreover, approximately 80% of individuals diagnosed with epilepsy reside in nations classified as low- and middle-income. According to research conducted in 2017, individuals diagnosed with epilepsy exhibit a higher propensity for experiencing migraines, particularly those who also manifest seizures coupled with aura. All these factors drive the global migraine with brainstem aura market.

Migraine and Brainstem Aura Market Restraint

Lack of Awareness

A relatively uncommon and intricate subtype of migraine is migraine with a brainstem aura. Sluggish awareness and comprehension of the condition may impede funding, research endeavors, and targeted treatment formulation. A limited number of approved therapies may be available to specifically target the unique characteristics and symptoms of migraine with brainstem aura due to its rarity. As a consequence, individuals who are impacted may be deprived of efficacious therapeutic alternatives.

Additionally, misdiagnoses, insufficient treatment, and postponed intervention may ensue from healthcare professionals and the general public's limited knowledge and comprehension of migraine with brainstem aura. Stroke symptoms that overlap with those of brainstem aura can make it difficult to diagnose migraine in this context. All these factors are expected to restrict market growth.

Migraine with Brainstem Aura Market Opportunities

Technological Advancements

Migraine with Brainstem Aura (MBA) diagnosis has advanced substantially over the last ten years, owing to developments in medical imaging technologies and the expansion of the field of neuroscience. Functional magnetic resonance imaging and diffusion tensor imaging are examples of sophisticated neuroimaging methods created by researchers to observe and evaluate the structure and function of the brain during an MBA. Diffusion MRI and functional MRI augment the capabilities of magnetic resonance imaging (MRI) by capturing detailed spatial images, neuronal tracts, and blood flow within the nervous system, respectively.

Furthermore, the key players are increasingly receiving regulatory approvals for their advanced diagnostic devices. For instance, in May 2022, Royal Philips, a global leader in health technology, declared that its new MR 7700 3.0T MR system had been granted FDA 510(k) clearance. This most recent breakthrough MR innovation from Philips provides unparalleled precision and performance for advanced clinical diagnostics and research. By leveraging Philips' cutting-edge neuroscience and high-precision diffusion imaging, the MR 7700's XP gradients enable precise diagnoses for each patient, contributing to cost savings and enhanced patient care. Such factors are expected to create opportunities for migraines with brainstem aura market growth.

Regional Analysis

North America Dominates the Global Market

Based on region, the global migraine with brainstem aura market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. 

North America is the most significant global migraine with brainstem aura market shareholder and is expected to expand substantially during the forecast period. North America, specifically the United States and Canada, are renowned for their highly developed healthcare systems and extensive medical knowledge. This entails the provision of services at headache clinics and specialized neurologists who are capable of diagnosing and treating migraines with brainstem aura. Patients suffering from migraine with brainstem aura in North America are provided with an extensive array of treatment alternatives, encompassing both preventive and acute pharmaceuticals, in addition to non-pharmacological approaches. The treatment options for migraine patients, including those with brainstem aura, have been broadened due to the introduction of more recent, targeted migraine medications, such as calcitonin gene-related peptide (CGRP) inhibitors.

In North America, clinical research and pharmaceutical development are concentrated. In this geographical area, research studies and clinical trials on migraine, encompassing migraine with brainstem aura, are carried out. For instance, the American Heart Association, a prominent nonprofit organization promoting cardiovascular and neurological well-being globally, has allocated USD 2.1 million to support seven novel scientific research initiatives. These studies aim to delve further into the intricate relationship between migraine and its potential implications on the susceptibility to stroke and cardiovascular ailments. The findings of these research endeavors enhance comprehension of the ailment and facilitate the creation of novel therapeutic interventions. All these factors boost market growth in the North American region.

The Asia-Pacific migraine with brainstem aura market is primarily boosted by the huge target population base in the region, advancing healthcare infrastructure, and growing awareness about the disease. In addition, the growing incidence of mental and neurological disorders in the region is also responsible for the growth of migraines in the brainstem aura market in the region. For example, according to the Global Burden of Disease study (2016), India is responsible for 15% of the worldwide disease burden associated with mental and neurological disorders (MNDs).

Furthermore, projections indicate that India's MND burden will increase by 23% by 2025. In accordance with a scholarly publication available in the National Library of Medicine (NLM), it has been reported that the estimated number of individuals affected by epilepsy in India amounts to roughly 10 million. This, in turn, drives the regional market expansion. However, socioeconomic factors and cultural perspectives regarding mental health and migraine may influence the quality of care and assistance provided to people with migraine in the Asia-Pacific area, thereby restricting market growth in the region.

Segmental Analysis

The global migraine with brainstem aura market is bifurcated into diagnosis, treatment, distribution channel, and end-user.

Based on diagnosis, the global migraine with brainstem aura market is bifurcated into magnetic resonance imaging (MRI), computerized tomography (CT), and others. 

MRI, or magnetic resonance imaging, is a medical imaging modality to visualize bodily internal structures. This imaging technique is classified as non-invasive and non-ionizing due to its lack of reliance on hazardous radiation sources such as X-rays or CT scans. MRI operates on the fundamental principles of radio waves and magnetism. Imaging soft tissues, including the brain, spinal cord, musculature, and internal organs, is a specific application of MRI. It is frequently employed across multiple medical disciplines, such as oncology, neurology, orthopedics, and cardiology, to diagnose and monitor various injuries and medical conditions. Since its introduction in the 1970s and 1980s, magnetic resonance imaging (MRI) has exhibited multifunctionality. While MRI is mostly used in diagnostic medicine and biomedical research, it can also be used to imagine nonliving entities, such as mummies.

Based on treatment, the global migraine with brainstem aura market is segmented into abortive medication and preventive medication. 

Preventive medication, alternatively referred to as prophylactic medication or preventative medicine, constitutes a category of medical interventions employed to avert the commencement or advancement of a particular ailment, state, or health concern. Patients who have a prior medical history of or are at an increased risk of developing a specific health condition are frequently prescribed this medication. In addition, preventive medication plays a pivotal role in individual healthcare plans and public health strategies, as it aids in managing chronic conditions, promotes health maintenance, and lessens the societal and individual burden of disease. Healthcare personnel commonly prescribe this medication following an individual's medical history, risk factors, and particular health requirements. The preventive medicine segment is further bifurcated into antidepressants, Botox injections, and others.

Based on distribution channels, the global migraine with brainstem aura market is bifurcated into retail pharmacies, hospital pharmacies, and others.

Hospital pharmacies are an indispensable component in healthcare facilities like hospitals and clinics, where they provide pharmaceutical services to support patient care. The hospitals and healthcare facilities entrust these pharmacies with the acquisition, storage, preparation, distribution, and administration of pharmaceuticals and medications. Hospital pharmacies are responsible for dispensing medications and verifying that patients are administered the appropriate medications, including the correct dosage and instructions. They execute medication orders in close collaboration with healthcare providers. To mitigate the occurrence of medication errors, hospital pharmacies employ safety protocols, including medication reconciliation.

Based on end-users, the global migraine with brainstem aura market is bifurcated into hospitals and clinics, diagnostic centers, and others.

Hospitals and clinics hold a significant share of the migraine with brainstem aura market, as most migraine with brainstem aura treatments are done in hospitals. Moreover, the growing number of hospitals and specialty clinics across developing countries positively impacts the demand for migraine and brainstem aura treatment procedures. As per the April 2020 report of the Center for Disease Dynamics, Economics, and Policy (CCDEP), there were 25,778 public sector hospitals in India. Moreover, efficient reimbursement programs that hospitals in some nations provide to patients, reducing their financial burden from medical expenses, support the expansion of the hospital market. Hence, from the factors above, the hospital segment is estimated to witness a high share over the forecasted period.

Recent Developments

• March 2023: Pfizer Inc.'s nasal spray for migraine was granted approval by the U.S. Food and Drug Administration. This development provides patients with a potentially suitable pain-relieving alternative for headaches. According to the manufacturer, Zavzpret has been approved for managing acute migraines.
• February 2023: Theranica, a provider of advanced neuromodulation devices for migraine and other pain conditions and a prescribed digital therapeutics company, announced that the Food and Drug Administration (FDA) had approved the Nerivio® prescription wearable for acute and preventive use in patients 12 years and older with migraine, aura, or no aura.